Bausch Health Companies Inc. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Other Comprehensive Income (Loss)
Bausch Health Companies Inc. (BHC) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Other Comprehensive Income (Loss) of $0 for the 9-month period ending 2024-09-30, per its 10-Q filed 2024-10-31.
Financial Statements › Income Statement › Other Income
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome · last filed 2024-10-31
- Bausch Health Companies Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in other comprehensive income (loss) for the quarter ending 2024-09-30 was $0.00.
- Bausch Health Companies Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in other comprehensive income (loss) for the quarter ending 2023-09-30 was $0.00.
- Bausch Health Companies Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in other comprehensive income (loss) for the quarter ending 2022-12-31 was $0.00.
- Bausch Health Companies Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in other comprehensive income (loss) for the quarter ending 2022-09-30 was $0.00.
- Bausch Health Companies Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in other comprehensive income (loss) for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- Bausch Health Companies Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in other comprehensive income (loss) for fiscal 2021 was $1.00M.
- Bausch Health Companies Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in other comprehensive income (loss) for fiscal 2018 was $0.00, a 100.00% decline from fiscal 2017.
- Bausch Health Companies Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in other comprehensive income (loss) for fiscal 2017 was $1.00M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Other Comprehensive Income (Loss) 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Other Comprehensive Income (Loss) 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Other Comprehensive Income (Loss) 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Other Comprehensive Income (Loss) 12 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Other Comprehensive Income (Loss) 12 month as first filed |
|---|---|---|---|---|---|
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $0.00 10-Q · filed 2024-10-31 | |||
| 2024-06-30 | $0.00 10-Q · filed 2024-08-01 | ||||
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $1.00M 10-Q · filed 2024-10-31 | |||
| 2023-06-30 | $1.00M 10-Q · filed 2024-08-01 | ||||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $0.00 derived: sum of 2 quarters · filed 2023-11-02 | $0.00 10-K · filed 2023-02-23 | ||
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $0.00 10-Q · filed 2023-11-02 | |||
| 2022-06-30 | $0.00 10-Q · filed 2023-08-03 | ||||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $0.00 derived: sum of 2 quarters · filed 2023-02-23 | $1.00M 10-K · filed 2023-02-23 | ||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $1.00M 10-Q · filed 2022-11-03 | |||
| 2021-06-30 | $1.00M 10-Q · filed 2022-08-09 | ||||
| 2020-12-31 | $0.00 derived: 8-K 12 month − 10-Q 9 month · filed 2022-05-11 | $0.00 derived: sum of 2 quarters · filed 2022-05-11 | $0.00 8-K · filed 2022-05-11 | ||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | $0.00 10-Q · filed 2021-11-02 | |||
| 2020-06-30 | $0.00 10-Q · filed 2021-08-03 | ||||
| 2019-12-31 | $1.00M 8-K · filed 2021-05-04 | ||||
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $0.00 10-Q · filed 2019-08-06 | |||
| 2019-03-31 | $0.00 10-Q · filed 2019-05-06 | ||||
| 2018-12-31 | $0.00 10-K · filed 2020-02-19 | ||||
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $1.00M 10-Q · filed 2019-08-06 | |||
| 2018-03-31 | $1.00M 10-Q · filed 2019-05-06 | ||||
| 2017-12-31 | $1.00M 10-K · filed 2019-02-20 | ||||
| 2016-12-31 | -$40.00M 8-K · filed 2018-08-10 | ||||
| 2015-12-31 | -$1.00M 10-K · filed 2017-03-01 | $1.10M 10-K · filed 2016-04-29 | |||
| 2014-12-31 | $4.10M 10-K · filed 2016-04-29 | ||||
| 2013-12-31 | $5.00M 10-K · filed 2015-02-25 | $4.94M 10-K · filed 2014-02-28 | |||
| 2012-12-31 | -$784.00K 10-K · filed 2014-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 |